Paper Details

  1. Home
  2. Paper Details

Treatment of septicaemia in immunocompromised patients with ceftazidime or with tobramycin and cefuroxime, with special reference to renal effects.

Author: AlestigK, BergmarkJ, BergströmT, HultbergB, JagenburgR, OlaissonL, RödjerS, TrollforsB, WestinJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ceftazidime and tobramycin and cefuroxime were found to be equally effective in treating 52 immunocompromised patients with suspected septicaemia. Both treatment groups had an increase in urinary alanine aminopeptidase, with a greater increase in the tobramycin and cefuroxime group.
Paper Details　
Original Abstract of the Article :
Fifty-two immunocompromised patients with suspected septicaemia were randomized on 61 occasions to treatment with ceftazidime or with tobramycin and cefuroxime. Most (90%) of the patients had haematological malignancies and were neutropenic (granulocytes less than 1 X 10(9)/1 in 40 of the 61 episode...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/20.1.109

データ提供：米国国立医学図書館（NLM）

Treating Septicemia in Immunocompromised Patients

This research delves into the challenging world of treating septicemia, a severe bloodstream infection, in patients with weakened immune systems. This study used a randomized trial, comparing the effectiveness of two antibiotic regimens – ceftazidime alone versus a combination of tobramycin and cefuroxime. The researchers wanted to find out which treatment was more effective and if either treatment had any negative effects on the kidneys. They discovered that both treatments were equally effective in treating septicemia and that neither regimen caused any major kidney problems.

Examining Kidney Effects of Antibiotic Regimens

While both treatment groups showed improvements in septicemia, there was a significant difference in the way their kidneys reacted. The tobramycin and cefuroxime group showed a higher increase in the urinary excretion of alanine aminopeptidase (AAP), a marker of potential kidney damage. This suggests that while both treatments may be effective, the combination therapy could potentially have more of an impact on kidney health.

Potential Risks and Considerations

While the study didn’t find any serious kidney issues, it's important to be mindful of the potential long-term effects of these antibiotics, especially the combination therapy. If you're on antibiotics for any reason, it's always a good idea to talk to your doctor about any concerns you may have about potential side effects.

Dr.Camel's Conclusion

Just like a camel navigating a desert, doctors need to carefully consider the risks and benefits when treating septicemia. This research reminds us that even when two treatments seem equally effective, there can be subtle differences in how our bodies react. It's like the difference between walking on soft sand and hard rocks – both get you to your destination, but one journey might leave you with more wear and tear.

Date :
  1. Date Completed 1987-10-21
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

3305460

DOI: Digital Object Identifier

10.1093/jac/20.1.109

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.